- Work 020 7329 4422
- Fax 020 7329 7100
- 64 CHANCERY LANE WC2
- Work +44 20 7809 2102
Andrew is a corporate partner who advises on public and private M&A, joint ventures and equity fundraisings. Andrew was the lead partner working on the deal that was shortlisted for corporate deal of the year 2010/11 by 'Legal Business' magazine. Andrew has been named by The Lawyer Magazine as one of the 'hot 100' lawyers for 2012 and was awarded the ILO client choice award for M&A 2012. Prior to joining Stephenson Harwood in 2010, Andrew was partner for eight years in another major international law firm. Transactions on which Andrew has advised include: Piramal Healthcare - $3.7bn disposal of its generic branded prescription pharmaceuticals division to Abbott; Nicholas Piramal India Limited (now Piramal Healthcare Limited) - acquisition of Pfizer's Northumberland manufacturing plant; FTSE-250 speciality pharmaceutical company, BTG plc - £177m public takeover of Biocompatibles International plc; Lavendon Group plc - successful defence against a hostile approach from TVH Services NV and Ashtead Group plc; Lavendon Group plc - £250m debt refinancing and placing and open offer; GDF SUEZ - the world's largest utility company - disposal of the Logan Teleflex group of companies to Tokyo-listed company Daifuku; Commerzbank - disposal of Kleinwort Benson to RHJ International; United Company Rusal Limited and its largest shareholder, EN+ Group Limited - $14bn acquisition of a 25 percent stake in Moscow-listed copper and nickel miner Norilsk Nickel; Rusal Limited - $30bn combination with Sual and the alumina assets of Glencore International, to form United Company Rusal, the world's largest aluminium producer; Biopharmaceutical company, Protherics plc - acquisition by BTG plc.
Corporate finance; M&A; Pharmaceuticals, biotechnology